Intuitive Surgical
ISRG
$353.33
+0.10%
Intuitive Surgical develops, produces, and markets the da Vinci robotic system for minimally invasive surgery, along with instrumentation, accessories, and warranty services. As the undisputed global leader in robotic-assisted surgery with over 10,000 da Vinci systems installed worldwide, the company enjoys a dominant competitive moat in the medical devices industry. The current investor narrative centers on growth deceleration concerns after management declined to raise full-year guidance despite a strong Q2 beat, while regulatory headwinds from an FDA safety alert on its stapler and competitive threats from Medtronic's Hugo robot add to the debate. However, the company's entrenched installed base, recurring revenue from instruments and services, and long-term procedure growth trajectory continue to attract both bulls and bears.…
ISRG
Intuitive Surgical
$353.33
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating: Hold. Intuitive Surgical is a high-quality business with a dominant market position, but the stock faces near-term headwinds from guidance disappointment, regulatory concerns, and a premium valuation. The consensus analyst rating is Buy with an average target of $484.40, implying 43.5% upside, but the wide target range ($324 to $685) reflects high uncertainty. The thesis is that the company's long-term growth trajectory and recurring revenue model justify a premium, but the current price does not offer a sufficient margin of safety given the risks.
Supporting Evidence: The company's revenue grew 22.96% YoY in Q1 2026, with operating margin expanding to 30.9% from 25.7% a year ago. Free cash flow of $2.83B TTM provides strong financial flexibility. The forward P/E of 28.1x is near the lower end of its historical range, suggesting that if the company delivers on estimated EPS of $17.00, the valuation could be reasonable. However, the trailing P/E of 70.8x indicates that the market is pricing in significant earnings growth over the next year. The PEG ratio of 3.17 is above 1, implying the stock is not cheap on a growth-adjusted basis. Compared to the medical devices industry, Intuitive trades at a substantial premium, but its dominant market position and high margins partially justify it.
Risks & Conditions: The biggest risks are: 1) failure to deliver on earnings expectations, leading to multiple compression; 2) FDA regulatory actions on the stapler; and 3) competitive pressure from Medtronic's Hugo robot. This Hold rating would upgrade to Buy if the stock falls below $300 (a 11% decline) or if the company raises guidance and demonstrates re-acceleration in procedure growth. It would downgrade to Sell if revenue growth decelerates below 15% or if the FDA issues a more severe warning. Overall, the stock appears fairly valued relative to its growth prospects, but the near-term risks warrant caution.
Sign up to view all
ISRG 12-Month Price Forecast
Intuitive Surgical presents a balanced risk/reward at current levels. The business fundamentals are strong with accelerating revenue growth, expanding margins, and a fortress balance sheet. However, the stock is in a deep downtrend due to guidance disappointment and regulatory overhang. The wide gap between trailing and forward P/E suggests the market expects a sharp earnings recovery, which is plausible but not guaranteed. The neutral stance reflects the tension between the attractive long-term opportunity and the near-term uncertainty. An upgrade to bullish would require the company to raise guidance or the stock to fall to a more compelling valuation (e.g., below $300). A downgrade to bearish would follow if growth decelerates below 15% or if regulatory issues worsen.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $477.25 and implied upside of +35.1% versus the current price.
Average Target
$477.25
0 analysts
Implied Upside
+35.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
Intuitive Surgical is covered by 28 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.91 on a 1-5 scale where 1 is Strong Buy). The average price target is $484.40, implying 43.5% upside from the current price of $337.50. The distribution leans bullish, with recent ratings from firms like TD Cowen (Buy), RBC Capital (Outperform), and B of A Securities (Buy) reaffirming positive views. However, Mizuho maintains a Neutral stance, reflecting some caution. The target range spans from a low of $324.00 to a high of $685.00, representing a wide spread of $361. The high target of $685 assumes the company can sustain its growth trajectory, expand margins, and maintain its competitive moat, potentially justifying a higher multiple. The low target of $324 suggests that if regulatory issues (FDA stapler concern) or competitive pressures from Medtronic's Hugo robot intensify, the stock could fall further. The wide range indicates high uncertainty among analysts about the company's near-term prospects. Recent rating actions have been mostly reaffirmations rather than upgrades or downgrades, suggesting analysts are waiting for more clarity on guidance and regulatory outcomes. The lack of recent downgrades despite the stock's decline implies that the sell-off is viewed as an overreaction by many, but the wide target spread cautions that conviction is not uniform.
Drowning in data?
Find the real signal!
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical presents a classic tension between a fundamentally strong business and a stock that has been punished by the market. On the bull side, the company boasts a dominant installed base, robust recurring revenue, expanding margins, and a fortress balance sheet with zero debt. The average analyst target implies 43.5% upside, and long-term procedure growth remains intact. On the bear side, the stock has been hit by a guidance disappointment, trades at a premium trailing P/E of 70.8x, faces FDA regulatory headwinds, and confronts a credible competitive threat from Medtronic's Hugo robot. The single most important factor that would resolve this debate is whether the company can re-accelerate procedure growth and deliver on earnings expectations, justifying its forward P/E of 28.1x. Currently, the bearish sentiment has stronger near-term evidence given the technical downtrend and guidance overhang, but the fundamental bull case provides a compelling long-term argument for patient investors.
Bullish
- Dominant installed base with recurring revenue: Intuitive Surgical has over 10,000 da Vinci systems installed globally, generating a recurring revenue stream from instruments and accessories ($1.69B in Q1 2026) and services ($434M). This provides a stable base and high switching costs for hospitals.
- Strong profitability and expanding margins: Operating margin improved to 30.9% in Q1 2026 from 25.7% a year ago, driven by operating leverage. Net income grew 17.6% YoY to $821.5M, with net margin at 29.6% (excluding prior year tax benefit).
- Fortress balance sheet with zero debt: The company has a debt-to-equity ratio of 0.017 (effectively zero debt) and a current ratio of 4.87. Free cash flow of $2.83B TTM provides ample liquidity for R&D and share repurchases ($1.12B in Q1 2026).
- Significant upside to analyst targets: The average analyst price target is $484.40, implying 43.5% upside from the current price of $337.50. The consensus rating is Buy (mean 1.91 on 1-5 scale), with 28 analysts covering the stock.
Bearish
- Guidance disappointment triggered sell-off: Management declined to raise full-year guidance despite a strong Q2 beat, causing the stock to drop 14.2% in a single day (July 17, 2026). This suggests growth deceleration ahead and eroded investor confidence.
- Premium valuation leaves no room for error: The trailing P/E of 70.8x is well above the industry average, and the PEG ratio of 3.17 indicates the stock is priced for above-average growth. Any earnings miss could trigger multiple compression and further downside.
- FDA safety alert on stapler product: In March 2026, the FDA flagged a safety concern over Intuitive's stapler, creating regulatory and reputational risk. While the company's dominant position may help, this could impact sales and increase scrutiny.
- Competitive threat from Medtronic's Hugo robot: Medtronic received FDA approval for its Hugo surgical robot, posing a direct challenge to Intuitive's monopoly. Although Intuitive's installed base is a formidable barrier, competition could pressure pricing and market share over time.
ISRG Technical Analysis
Intuitive Surgical is in a sustained downtrend, with the stock declining 30.9% over the past year compared to the S&P 500's gain of 16.5%. The current price of $337.50 sits at just 1.5% above its 52-week low of $328.57 and 44.1% below the 52-week high of $603.88, indicating the stock is near the bottom of its range. This positioning suggests the market is pricing in significant pessimism, but also raises the risk of further downside if fundamentals deteriorate. Short-term momentum is decisively negative, with the stock falling 16.0% in the last month and 30.0% in the last three months. The 1-month decline of 16.0% is far worse than the S&P 500's gain of 0.8%, resulting in a relative strength of -16.8% over the month. This sharp divergence from the broader market signals that company-specific factors—such as the guidance disappointment and FDA concerns—are driving selling pressure, and there is no sign of a reversal yet. The stock's beta of 1.46 indicates it is 46% more volatile than the market, amplifying both upside and downside moves. Key support lies at the 52-week low of $328.57, a break below which could open the door to further declines. Resistance is at the 52-week high of $603.88, but a more near-term resistance level is the $400 area, which acted as support in June before breaking down. A move above $400 would be a first sign of stabilization, while a break below $328.57 would likely accelerate selling.
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-26.6%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -12.2% | +0.2% |
| 3m | -22.8% | +3.7% |
| 6m | -29.9% | +8.0% |
| 1y | -26.6% | +18.2% |
| ytd | -37.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust but is showing signs of deceleration. In Q1 2026, revenue reached $2.77 billion, up 22.96% year-over-year, compared to 18.9% growth in Q1 2025. However, the sequential trend from Q4 2025's $2.87 billion shows a slight decline, and the company's decision not to raise full-year guidance suggests management expects growth to moderate. The revenue breakdown shows Instruments and Accessories ($1.69 billion) as the largest segment, followed by Systems ($651 million) and Services ($434 million), highlighting the recurring revenue base from the installed system fleet. Profitability is strong and improving. Net income for Q1 2026 was $821.5 million, up from $698.4 million in Q1 2025, with net margin expanding to 29.6% from 31.0% a year ago (though the prior year had a tax benefit). Gross margin remains healthy at 66.1%, and operating margin improved to 30.9% from 25.7% a year ago, driven by operating leverage. The company is consistently profitable with positive net income and expanding margins, which supports its premium valuation. The balance sheet is fortress-like with zero debt (debt-to-equity ratio of 0.017) and a current ratio of 4.87, indicating ample liquidity. Free cash flow for the trailing twelve months is $2.83 billion, and Q1 2026 operating cash flow of $911.9 million easily covers capital expenditures of $103.3 million. Return on equity stands at 16.0%, reflecting efficient capital allocation. The company does not pay a dividend, instead reinvesting cash into growth and share repurchases ($1.12 billion in Q1 2026). This financial strength provides a cushion against near-term headwinds and funds R&D and strategic investments.
Quarterly Revenue
$2.8B
2026-03
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
66.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Since net income is positive ($821.5 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 70.8x, while the forward P/E is 28.1x, implying the market expects significant earnings growth over the next year. The gap between trailing and forward P/E is unusually wide, reflecting expectations of a sharp earnings increase driven by margin expansion and revenue growth. Compared to the medical devices industry, Intuitive Surgical trades at a substantial premium. The industry average P/E is not provided, but the company's PEG ratio of 3.17 suggests it is priced for above-average growth. The P/S ratio of 20.1x and EV/EBITDA of 49.9x further underscore the premium valuation. This premium is partially justified by the company's dominant market position, high margins, and recurring revenue model, but it leaves little room for error. Historically, the stock's trailing P/E has ranged from roughly 49x to 84x over the past five years. The current 70.8x is near the middle of that range but above the 49x low seen in late 2023. The forward P/E of 28.1x is near the lower end of its historical forward range, suggesting that if the company delivers on earnings expectations, the valuation could compress further. However, the high absolute multiples mean the stock is priced for perfection, and any disappointment could lead to multiple contraction.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intuitive Surgical's primary financial risk is valuation compression. With a trailing P/E of 70.8x and a PEG ratio of 3.17, the stock is priced for perfection. If earnings growth disappoints—for example, if revenue growth decelerates below 20%—the multiple could contract significantly, leading to substantial downside. The company's reliance on procedure volume growth means any slowdown in hospital capital spending or surgical volume (e.g., due to macro uncertainty) would directly impact revenue. Additionally, the company does not pay a dividend, so total return depends entirely on price appreciation. However, the balance sheet is pristine with zero debt and $2.83B in free cash flow, mitigating financial distress risk.
Market & Competitive Risks: The most significant market risk is the competitive threat from Medtronic's Hugo robot, which received FDA approval and could erode Intuitive's market share over time. Although Intuitive's installed base of over 10,000 systems creates high switching costs, hospitals may use competition to negotiate lower prices, pressuring margins. Regulatory risk is elevated following the FDA safety alert on the company's stapler in March 2026, which could lead to additional scrutiny or product recalls. The stock's beta of 1.46 indicates high sensitivity to market downturns, and the recent 30.9% decline versus the S&P 500's 16.5% gain shows company-specific factors are amplifying macro weakness. Sector rotation away from growth stocks could further pressure the multiple.
Worst-Case Scenario: In a severe scenario, the company could face a combination of factors: a broader market correction, intensifying competition from Medtronic, adverse FDA actions on the stapler, and a deceleration in procedure growth leading to an earnings miss. Under these conditions, the stock could fall to the analyst low target of $324.00, representing a 4.0% decline from the current price of $337.50. However, given the stock's 52-week low of $328.57, a break below that level could trigger further selling, potentially testing the $300 area (a 11% decline). The maximum drawdown from the 52-week high of $603.88 is already 44.1%, and in a worst-case scenario, losses could extend to 50% from the high, implying a price near $302. An investor buying at $337.50 could face a loss of up to 10-15% in an adverse scenario.
FAQ
The key risks of holding Intuitive Surgical are: 1) Valuation risk: The trailing P/E of 70.8x leaves little room for error; any earnings disappointment could lead to multiple compression and significant downside. 2) Regulatory risk: The FDA safety alert on the company's stapler in March 2026 could escalate into a recall or additional restrictions, impacting revenue and reputation. 3) Competitive risk: Medtronic's Hugo robot, which received FDA approval, poses a long-term threat to Intuitive's market share, potentially pressuring pricing and growth. 4) Growth deceleration risk: Management's decision not to raise full-year guidance despite a strong Q2 suggests growth may slow, and if revenue growth falls below 15%, the stock could re-rate lower. The most severe risk is a combination of these factors, which could drive the stock to the analyst low target of $324 or below.
The 12-month forecast for Intuitive Surgical is mixed, with three scenarios. The base case (50% probability) sees the stock recovering to the analyst average target of $484.40, driven by continued revenue growth of 18-20% and stable margins. The bull case (25% probability) targets $480-$685, assuming the company raises guidance and resolves regulatory concerns. The bear case (25% probability) sees the stock falling to $324-$370 if growth decelerates or regulatory issues worsen. The consensus analyst rating is Buy, with an average target implying 43.5% upside. However, the wide target range ($324 to $685) reflects high uncertainty. The most likely outcome is the base case, where the stock gradually recovers as the market digests the guidance disappointment and focuses on the long-term opportunity.
Intuitive Surgical's valuation is a mixed picture. On a trailing basis, the P/E of 70.8x is high and suggests the stock is overvalued relative to historical averages and the broader market. However, the forward P/E of 28.1x is much lower, reflecting expectations of strong earnings growth (estimated EPS of $17.00 for the next year). The PEG ratio of 3.17 indicates the stock is priced for above-average growth, but not excessively so compared to its historical range. Compared to the medical devices industry, Intuitive trades at a substantial premium, but this is partially justified by its dominant market position, high margins (gross margin 66.1%), and recurring revenue. Overall, the stock appears fairly valued on a forward basis if the company delivers on earnings expectations, but overvalued on a trailing basis. The market is pricing in a sharp earnings recovery, which is the key risk.
Intuitive Surgical is a good stock to buy for long-term investors who can tolerate volatility and have a 3-5 year horizon. The company's dominant market position, recurring revenue model, and strong financials (zero debt, $2.83B free cash flow) provide a solid foundation. The current price of $337.50 is near the 52-week low and offers 43.5% upside to the average analyst target of $484.40. However, the stock faces near-term headwinds from guidance disappointment, FDA regulatory concerns, and a premium trailing P/E of 70.8x. For risk-averse investors or those with a short-term horizon, it may be better to wait for more clarity on guidance and regulatory outcomes. The stock is not a good buy for those seeking immediate returns, but for those willing to hold through volatility, the risk/reward is attractive.
Intuitive Surgical is more suitable for long-term investment than short-term trading. The company's growth stage is mature but still expanding, with a beta of 1.46 indicating high volatility. The stock does not pay a dividend, so returns depend entirely on price appreciation. Short-term traders face significant risk from the ongoing downtrend and negative momentum (stock down 16% in the last month). However, for long-term investors (3-5 years), the company's dominant market position, recurring revenue, and strong financials provide a compelling case. The current price near the 52-week low offers a potential entry point for patient investors. A suggested minimum holding period is 3 years, allowing time for the company to navigate regulatory and competitive challenges and for the earnings growth to justify the valuation.
